Neonatal Screening for Congenital Adrenal Hyperplasia in Denmark: 10 Years of Experience

Introduction: Early detection of salt-wasting congenital adrenal hyperplasia (SW-CAH) is important to reduce CAH-related morbidity. However, neonatal screening has shown to have a low positive predictive value (PPV), especially among preterm newborns. Here, the Danish CAH screening is evaluated by comparing incidence and morbidity of SW-CAH 10 years before and after introduction of screening. Furthermore, sensitivity, specificity, and PPV are determined. Methods: All newborns in Denmark born during 1999–2018 and diagnosed with SW-CAH were identified in the Danish National Patient Registry and/or at the Department of Clinical Genetics, Rigshospitalet. Newborns with a positive neonatal CAH screening were identified at Statens Serum Institut. Correct diagnosis was evaluated by medical record review. Results: A total of 65 newborns with SW-CAH were identified. The incidence of SW-CAH was 5:100,000 both before and after introduction of screening. Performance of sensitivity and specificity of the screening were 97% and 100%, respectively, and the PPV was 55% for the given period. Stratified according to gestational age, the PPV was 33% and 61% for pre -and fullterm newborns, respectively. Though not significant, the proportion of newborns presenting with SW-crisis decreased after introduction of screening from 29% versus 10% (p = 0.07). Discussion and Conclusion: Neonatal screening for SW-CAH has not led to an increase in the incidence of newborns diagnosed with SW-CAH. The screening algorithm has effectively identified newborns with SW-CAH. After 2009, there was a tendency toward a lower proportion of newborns with SW-crisis at diagnosis. Finally, the study emphasizes the benefits of using second-tier screening as well as repeated screening of premature newborns.

[1]  P. Hofman,et al.  Birthweight or Gestational Age Adjusted Second Tier LCMSMS Cut-offs Improve Newborn Screening for CAH in New Zealand. , 2021, The Journal of clinical endocrinology and metabolism.

[2]  I. Bird,et al.  Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy , 2020, International journal of neonatal screening.

[3]  V. Wiley,et al.  Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme , 2020, International journal of neonatal screening.

[4]  H. Vallance,et al.  Clinical Impact and Cost Efficacy of Newborn Screening for Congenital Adrenal Hyperplasia. , 2020, The Journal of pediatrics.

[5]  P. Hofman,et al.  Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand , 2020, International journal of neonatal screening.

[6]  D. Hougaard,et al.  Danish expanded newborn screening is a successful preventive public health programme. , 2020, Danish medical journal.

[7]  Sichi Liu,et al.  The adjustment of 17-hydroxyprogesterone cut-off values for congenital adrenal hyperplasia neonatal screening by GSP according to gestational age and age at sampling , 2019, Journal of pediatric endocrinology & metabolism : JPEM.

[8]  S. Almashanu,et al.  Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia. , 2019, The Journal of clinical endocrinology and metabolism.

[9]  M. Finken,et al.  Evaluation of the Dutch neonatal screening for congenital adrenal hyperplasia , 2019, Archives of Disease in Childhood.

[10]  Norma P. Tavakoli,et al.  Newborn screening for congenital adrenal hyperplasia in New York State , 2016, Molecular genetics and metabolism reports.

[11]  Yannan Jiang,et al.  Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. , 2015, The Journal of clinical endocrinology and metabolism.

[12]  A. Nordenström,et al.  Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study. , 2014, JAMA pediatrics.

[13]  W. Thomas,et al.  Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants. , 2014, The Journal of pediatrics.

[14]  P. Clayton,et al.  No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening , 2013, Archives of Disease in Childhood.

[15]  H. Falhammar,et al.  One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. , 2013, The lancet. Diabetes & endocrinology.

[16]  Flemming Skovby,et al.  Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. , 2012, Molecular genetics and metabolism.

[17]  W. Thomas,et al.  Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal Hyperplasia , 2012, Pediatrics.

[18]  I. Silva,et al.  Neonatal screening for congenital adrenal hyperplasia. , 2012, Revista da Associacao Medica Brasileira.

[19]  J. Coste,et al.  Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. , 2012, Archives of pediatrics & adolescent medicine.

[20]  P. Hindmarsh,et al.  Incidence and clinical features of congenital adrenal hyperplasia in Great Britain , 2012, Archives of Disease in Childhood.

[21]  V. Montori,et al.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[22]  M. Morris,et al.  Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[23]  E. Elliott,et al.  Two‐year pilot study of newborn screening for congenital adrenal hyperlasia in New South Wales compared with nationwide case surveillance in Australia , 2008, Journal of paediatrics and child health.

[24]  M. Peter,et al.  Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  J. Wit,et al.  Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  B. Casetta,et al.  Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. , 2004, Clinical chemistry.

[27]  E. Schoenle,et al.  High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. , 2002, The Journal of clinical endocrinology and metabolism.

[28]  S. Berenbaum,et al.  Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia , 1998, Pediatrics.

[29]  A. Nordenström,et al.  Benefits of Neonatal Screening for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in Sweden , 1998, Pediatrics.

[30]  A. Larsson,et al.  Congenital Adrenal Hyperplasia in Sweden 1969‐1986 Prevalence, Symptoms and Age at Diagnosis , 1990, Acta paediatrica Scandinavica.

[31]  M. New,et al.  Congenital adrenal hyperplasia. , 1988, Biochemical Society transactions.